Vivo Opportunity funds disclose 24% stake in InMed Pharmaceuticals
Vivo Opportunity Fund Holdings, L.P. and affiliated entities disclosed ownership of 790,979 common shares of InMed Pharmaceuticals, representing 24% of the outstanding class, acquired on the open market between May 19 and June 8, 2026. The purchases followed InMed's announcement of a merger agreement with Mentari Therapeutics. Vivo Opportunity entities are also committed to participate in a pre-closing financing of Mentari shares, which will convert into InMed common shares at closing under the merger's exchange ratio.
Key facts
- Vivo Opportunity Fund Holdings, L.P.: 718,444 shares, 21.7% of class
- Vivo Opportunity Cayman Fund, L.P.: 72,535 shares, 2.2% of class
- Combined aggregate: 790,979 shares, 24% of outstanding class
- Shares acquired May 19–June 8, 2026, on open market after merger announcement
- Reporting persons committed to Mentari Securities Purchase Agreement pre-closing financing
- Merger Agreement executed May 19, 2026, between InMed, Mentari Therapeutics, and merger subsidiaries
- Vivo entities hold shares for investment purposes
Why it matters
Vivo Opportunity's 24% stake makes it a substantial shareholder in InMed at a critical juncture — the Mentari merger — and the group's concurrent commitment to finance Mentari's equity positions it as a significant stakeholder in the transaction's success and the combined company's capitalization.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from SCHEDULE 13D filed 2026-06-10. Not investment advice. View the source filing on SEC.gov →